Use of Neuromuscular Blocking Agents in the Intensive Care Unit

  • Rodger E. Barnette
  • Gerard J. Criner


In the mid-1980s, the two intermediate-duration neuromuscular blocking (NMB) agents atracurium and vecuronium were introduced into practice; within a few years, these accounted for the majority of NMB agent use in critically ill patients. In association with the introduction of these new agents, there was an expansion of the indications for muscle paralysis in this country, which was at least partially related to new ventilatory modes and technologic advances that necessitated cooperative, sedate, or immobile patients. These new indications for an immobile patient, coupled with an expanded knowledge of available NMB agents, led to a dramatic increase in the use of muscle paralysis in the intensive care unit (ICU). In association with that increased use came a growing awareness of the potential for severe complications and side effects.


Ulnar Nerve Neuromuscular Blockade Nicotinic Acetylcholine Receptor Adult Respiratory Distress Syndrome Neuromuscular Blocking Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Barohn RJ, Jackson CE, Rogers SJ, et al. Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids. Muscle Nerve 1994; 17: 647–654.PubMedCrossRefGoogle Scholar
  2. Caldwell JE, Szenohradszky J, Segredo V, et al. The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vcuronium, in human volunteers. JPET 1994: 270; 1216–1222.Google Scholar
  3. Gooch JL. AAEM case report # 29: prolonged paralysis after neuromuscular blockade. Muscle Nerve 1995; 18: 937–942.PubMedCrossRefGoogle Scholar
  4. Hoyt JW. Persistent paralysis in critically ill patients after the use of neuromuscular blocking agents. New Horiz 1994; 2: 48–55.PubMedGoogle Scholar
  5. Lee C. Intensive care unit neuromuscular syndrome? Anesthesiology 1995; 83: 237–240.PubMedCrossRefGoogle Scholar
  6. Lopez DM, Singer LP, Weingarten-Arams JS, et al. Use of neuromuscular blocking agents and sedation in pediatric patients and associated prolonged neuromuscular weakness. Pharm Ther 1999; 24: 290–296.Google Scholar
  7. Martyn JAJ, White DA, Gronert GA, et al. Up-and-down regulation of skeletal muscle acetylcholine receptors. Anesthesiology 1992; 76: 822–843.PubMedCrossRefGoogle Scholar
  8. Rich MM, Teener JW, Raps EC, et al. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996; 46: 731–736.PubMedCrossRefGoogle Scholar
  9. Standaert FG. Doughnuts and holes: molecules and muscle relaxants. Semin Anaesth 1994; 13: 286–296.Google Scholar
  10. Tsukagoshi H, Morita T, Takahashi K, et al. Cecal ligation and puncture peritonitis model shows decreased nicotinic acetylcholine receptor numbers in rat muscle. Anesthesiology 1999; 91: 448–460.PubMedCrossRefGoogle Scholar
  11. Wagner BKJ, Zavotsky KE, Sweeney JB, et al. Patient recall of therapeutic paralysis in a surgical critical care unit. Pharmacotherapy 1998; 18: 358–363.PubMedGoogle Scholar
  12. Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med 1994; 22: 884–893.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Rodger E. Barnette
  • Gerard J. Criner

There are no affiliations available

Personalised recommendations